ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS.

Trial Profile

ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (ROZEX), IN PATIENTS WITH PAPULO-PUSTULAR ROSACEA OVER 12 WEEKS.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2011

At a glance

  • Drugs Ivermectin; Metronidazole
  • Indications Bacterial infections; Rosacea
  • Focus Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top